Autor(es):Mostrar menos -

Sales, Lucas P. ; Souza, Lucas V. B. ; Fernandes, Alan L. ; Murai, Igor H. ; Santos, Mayara D. ; Vendramini, Margarete B. G. ; Oliveira, Ricardo M. ; Figueiredo, Camille P. ; Caparbo, Valeria F. ; Gualano, Bruno ; Pereira, Rosa M. R.

• Tipo de documento: Artigo Científico
• Fonte: Clinics; v. 79, p. 7-pg., 2024-08-28.

Resumo

Objective: To investigate the effect of a single oral dose of 200,000 IU of vitamin D-3 on antiphospholipid antibodies in hospitalized patients with moderate to severe COVID-19. Methods: This is a post-hoc, exploratory analysis from a double-blind, placebo-controlled, randomized clinical trial performed in two centers in Sao Paulo, Brazil. Hospitalized patients with COVID-19 were randomly assigned to receive either vitamin D-3 (n = 97) or placebo (n = 97). In this post-hoc analysis, the endpoints were titers and frequency of anti-beta 2-Glycoprotein-I (a beta 2-GP) and Anticardiolipin (aCL) antibodies [Immunoglobulin G, M and A (IgG, IgM and IgA)]. Results: Overall mean (SD) age was 55.3 (13.9) years, Body Mass Index (BMI) was 32.2 (7.1 kg/m(2)), and 106 participants (54.6 %) were male. There was a significant group by time interaction (p = 0.046) for frequency of aCL IgG, with increased values from baseline to discharge in the placebo group [n (%), from 13 (13.4) to 25 (25.8)] compared to the vitamin D-3 [from 25 (25.8) to 29 (29.9)]. However, the frequency of aCL IgG did not change between the groups on discharge. No significant differences between vitamin D3 and placebo groups were found for any other autoantibodies. Conclusion: These findings do not support the use of a single oral dose of 200,000 IU of vitamin D-3 to modulate autoantibodies in hospitalized patients with moderate to severe COVID-19. (AU)

• Processo FAPESP: 19/24782-4 - Comparação dos mecanismos de perda óssea em pacientes submetidos à derivação gástrica em Y de Roux ou gastrectomia vertical
• Beneficiário: Igor Hisashi Murai
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 20/11102-2 - Suplementação com vitamina D em pacientes com COVID-19: ensaio clínico, randomizado, duplo-cego e controlado por placebo
• Beneficiário: Alan Lins Fernandes
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 20/07098-0 - Impacto da Obesidade, Sarcopenia, e Obesidade Sarcopênica nos marcadores de saúde e qualidade de vida de idosas com síndrome de fragilidade não institucionalizadas
• Beneficiário: Alan Lins Fernandes
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 20/05752-4 - Suplementação com vitamina D em pacientes com COVID-19: ensaio clínico, randomizado, duplo-cego e controlado por placebo
• Beneficiário: Rosa Maria Rodrigues Pereira
• Modalidade de apoio: Auxílio à Pesquisa - Regular